Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson’s Disease
Tóm tắt
Long noncoding RNAs (lncRNAs) are implicated in the autophagic-lysosomal pathway (ALP) and are closely linked to Parkinson’s disease (PD) pathology. β-Glucocerebrosidase (GCase) has also been reported to be correlated with α-synuclein (α-syn) proteostasis. However, lncRNAs and α-syn in neural-derived L1CAM exosomes and GCase activity in the plasma of PD patients have not been studied. This study used an ultrasensitive methodology, fluorescence nanoparticle tracking analysis (NTA), to measure plasma L1CAM exosomes and Quanterix Simoa to measure α-syn concentrations in L1CAM exosomes. Eighty-five healthy controls and 93 PD patients were enrolled, and several scales were used to rate the severity of PD. Receiver operating characteristic (ROC) curves were applied to map the diagnostic accuracy of categorizing PD patients and healthy subjects. We found increased Linc-POU3F3 and α-syn concentrations in L1CAM exosomes and decreased GCase activity in PD patients compared with controls. The three biomarkers displayed obvious differences among PD patients based on gender, H-Y stage, and UPDRS-III distribution. Interestingly, Linc-POU3F3 was significantly positively correlated with α-syn in L1CAM exosomes and inversely correlated with GCase activity in PD patients. Significant correlations were observed among L1CAM exosomal Linc-POU3F3 levels, GCase activity, and PD severity, including motor/cognitive dysfunction. Additionally, the combination of Linc-POU3F3 and α-syn in L1CAM exosomes and GCase activity could discriminate PD patients from controls. These results suggest that L1CAM exosomal Linc-POU3F3, L1CAM exosomal α-syn, and GCase activity may shed light on the mechanism underlying the autophagic-lysosomal system in the pathogenesis of PD and could be used to assess the severity of PD.
Tài liệu tham khảo
Conte A, Khan N, Defazio G, Rothwell JC, Berardelli A. Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat Rev Neurol. 2013; 9:687–697. https://doi.org/10.1038/nrneurol.2013.224
Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009; 18:R48–59. https://doi.org/10.1093/hmg/ddp012
Zhou H, Shao M, Guo B et al. Tetramethylpyrazine Analogue T-006 Promotes the Clearance of Alpha-synuclein by Enhancing Proteasome Activity in Parkinson’s Disease Models. Neurotherapeutics. 2019. https://doi.org/10.1007/s13311-019-00759-8
Papadopoulos VE, Nikolopoulou G, Antoniadou I et al. Modulation of beta-glucocerebrosidase increases alpha-synuclein secretion and exosome release in mouse models of Parkinson’s disease. Hum Mol Genet. 2018; 27:1696–1710. https://doi.org/10.1093/hmg/ddy075
Stuendl A, Kunadt M, Kruse N et al. Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies. Brain. 2016; 139:481–494. https://doi.org/10.1093/brain/awv346
Ngolab J, Trinh I, Rockenstein E et al. Brain-derived exosomes from dementia with Lewy bodies propagate alpha-synuclein pathology. Acta Neuropathol Commun. 2017; 5:46. https://doi.org/10.1186/s40478-017-0445-5
Shi M, Liu C, Cook TJ et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014; 128:639–650. https://doi.org/10.1007/s00401-014-1314-y
Shi M, Kovac A, Korff A et al. CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement. 2016; 12:1125–1131. https://doi.org/10.1016/j.jalz.2016.04.003
Ng ASL, Tan YJ, Lu Z et al. Plasma alpha-synuclein detected by single molecule array is increased in PD. Ann Clin Transl Neurol. 2019; 6:615–619. https://doi.org/10.1002/acn3.729
Xia Y, Zhang G, Han C et al. Microglia as modulators of exosomal alpha-synuclein transmission. Cell Death Dis. 2019; 10:174. https://doi.org/10.1038/s41419-019-1404-9
Riva P, Battaglia C, Venturin M. Emerging Role of Genetic Alterations Affecting Exosome Biology in Neurodegenerative Diseases. Int J Mol Sci. 2019; 20. https://doi.org/10.3390/ijms20174113
Parnetti L, Paciotti S, Eusebi P et al. Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson’s disease patients. Mov Disord. 2017; 32:1423–1431. https://doi.org/10.1002/mds.27136
Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA Structures and Interactions by Sequencing-Based Approaches. Trends Biochem Sci. 2019; 44:33–52. https://doi.org/10.1016/j.tibs.2018.09.012
Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013; 152:1298–1307. https://doi.org/10.1016/j.cell.2013.02.012
Qureshi IA, Mehler MF. Long non-coding RNAs: novel targets for nervous system disease diagnosis and therapy. Neurotherapeutics. 2013; 10:632–646. https://doi.org/10.1007/s13311-013-0199-0
Zhao R, Zhang Y, Zhang X et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer. 2018; 17:68. https://doi.org/10.1186/s12943-018-0817-x
Liu T, Zhang X, Gao S et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016; 7:85551–85563. https://doi.org/10.18632/oncotarget.13465
Guo H, Wu L, Yang Q, Ye M, Zhu X. Functional linc-POU3F3 is overexpressed and contributes to tumorigenesis in glioma. Gene. 2015; 554:114–119. https://doi.org/10.1016/j.gene.2014.10.038
Shan TD, Xu JH, Yu T et al. Knockdown of linc-POU3F3 suppresses the proliferation, apoptosis, and migration resistance of colorectal cancer. Oncotarget. 2016; 7:961–975. https://doi.org/10.18632/oncotarget.5830
Lang HL, Hu GW, Chen Y et al. Glioma cells promote angiogenesis through the release of exosomes containing long non-coding RNA POU3F3. Eur Rev Med Pharmacol Sci. 2017; 21:959–972
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56:33–39. https://doi.org/10.1001/archneur.56.1.33
Postuma RB, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015; 30:1591–1601. https://doi.org/10.1002/mds.26424
Postuma RB, Poewe W, Litvan I et al. Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2018; 33:1601–1608. https://doi.org/10.1002/mds.27362
Manna I, Iaccino E, Dattilo V et al. Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. Faseb j. 2018; 32:4241–4246. https://doi.org/10.1096/fj.201701533R
Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques. Theranostics. 2017; 7:789–804. https://doi.org/10.7150/thno.18133
Manier S, Liu CJ, Avet-Loiseau H et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017; 129:2429–2436. https://doi.org/10.1182/blood-2016-09-742296
Qin Z, Balimunkwe RM, Quan T. Age-related reduction of dermal fibroblast size upregulates multiple matrix metalloproteinases as observed in aged human skin in vivo. Br J Dermatol. 2017; 177:1337–1348. https://doi.org/10.1111/bjd.15379
Beekman C, Janson AA, Baghat A, van Deutekom JC, Datson NA. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy. PLoS One. 2018; 13:e0195850. https://doi.org/10.1371/journal.pone.0195850
Devic I, Hwang H, Edgar JS et al. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain. 2011; 134:e178. https://doi.org/10.1093/brain/awr015
Lin X, Cook TJ, Zabetian CP et al. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Scientific Reports. 2012; 2:954
Kim HJ, Jeon B, Song J et al. Leukocyte glucocerebrosidase and beta-hexosaminidase activity in sporadic and genetic Parkinson disease. Parkinsonism Relat Disord. 2016; 23:99–101. https://doi.org/10.1016/j.parkreldis.2015.12.002
Kenwrick S, Watkins A, De Angelis E. Neural cell recognition molecule L1: relating biological complexity to human disease mutations. Hum Mol Genet. 2000; 9:879–886. https://doi.org/10.1093/hmg/9.6.879
Lachenal G, Pernet-Gallay K, Chivet M et al. Release of exosomes from differentiated neurons and its regulation by synaptic glutamatergic activity. Mol Cell Neurosci. 2011; 46:409–418. https://doi.org/10.1016/j.mcn.2010.11.004
Baldwin S, Deighan C, Bandeira E et al. Analyzing the miRNA content of extracellular vesicles by fluorescence nanoparticle tracking. Nanomedicine. 2017; 13:765–770. https://doi.org/10.1016/j.nano.2016.10.013
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016; 6:287–296. https://doi.org/10.1016/j.apsb.2016.02.001
Caruso Bavisotto C, Scalia F, Marino Gammazza A et al. Extracellular Vesicle-Mediated Cell(−)Cell Communication in the Nervous System: Focus on Neurological Diseases. Int J Mol Sci. 2019; 20. https://doi.org/10.3390/ijms20020434
Wortzel I, Dror S, Kenific CM, Lyden D. Exosome-Mediated Metastasis: Communication from a Distance. Dev Cell. 2019; 49:347–360. https://doi.org/10.1016/j.devcel.2019.04.011
Dragovic RA, Gardiner C, Brooks AS et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine. 2011; 7:780–788. https://doi.org/10.1016/j.nano.2011.04.003
Witwer KW, Buzas EI, Bemis LT et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013; 2. https://doi.org/10.3402/jev.v2i0.20360
Rissin DM, Kan CW, Campbell TG et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010; 28:595–599. https://doi.org/10.1038/nbt.1641
Zetterberg H, Wilson D, Andreasson U et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013; 5:9. https://doi.org/10.1186/alzrt163
Sun Z, Yang S, Zhou Q et al. Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer. 2018; 17:82. https://doi.org/10.1186/s12943-018-0831-z
Zheng R, Du M, Wang X et al. Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer. 2018; 17:143. https://doi.org/10.1186/s12943-018-0880-3
Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010; 133:713–726. https://doi.org/10.1093/brain/awq008
Barbour R, Kling K, Anderson JP et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008; 5:55–59. https://doi.org/10.1159/000112832
Zhao ZH, Chen ZT, Zhou RL et al. Increased DJ-1 and alpha-Synuclein in Plasma Neural-Derived Exosomes as Potential Markers for Parkinson’s Disease. Front Aging Neurosci. 2018; 10:438. https://doi.org/10.3389/fnagi.2018.00438
Cerri S, Ghezzi C, Sampieri M et al. The Exosomal/Total alpha-Synuclein Ratio in Plasma Is Associated With Glucocerebrosidase Activity and Correlates With Measures of Disease Severity in PD Patients. Front Cell Neurosci. 2018; 12:125. https://doi.org/10.3389/fncel.2018.00125
Rockenstein E, Clarke J, Viel C et al. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson’s disease. Hum Mol Genet. 2016; 25:2645–2660. https://doi.org/10.1093/hmg/ddw124
Papagiannakis N, Xilouri M, Koros C et al. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson’s disease patients. Mov Disord. 2015; 30:1830–1834. https://doi.org/10.1002/mds.26433
Niimi Y, Ito S, Mizutani Y et al. Altered regulation of serum lysosomal acid hydrolase activities in Parkinson’s disease: A potential peripheral biomarker? Parkinsonism Relat Disord. 2019; 61:132–137. https://doi.org/10.1016/j.parkreldis.2018.10.032
Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 2008; 131:1969–1978. https://doi.org/10.1093/brain/awm318
Bellomo G, Paciotti S, Gatticchi L, Parnetti L. The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction. Mov Disord. 2019. https://doi.org/10.1002/mds.27895
Fussi N, Hollerhage M, Chakroun T et al. Exosomal secretion of alpha-synuclein as protective mechanism after upstream blockage of macroautophagy. Cell Death Dis. 2018; 9:757. https://doi.org/10.1038/s41419-018-0816-2
Bae EJ, Yang NY, Lee C et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and alpha-synuclein aggregation. Exp Mol Med. 2015; 47:e153. https://doi.org/10.1038/emm.2014.128
Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. Brain. 2014; 137:1304–1322. https://doi.org/10.1093/brain/awu002
Bae EJ, Yang NY, Song M et al. Glucocerebrosidase depletion enhances cell-to-cell transmission of alpha-synuclein. Nat Commun. 2014; 5:4755. https://doi.org/10.1038/ncomms5755
Du TT, Wang L, Duan CL et al. GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy. 2015; 11:1803–1820. https://doi.org/10.1080/15548627.2015.1086055
Alvarez-Erviti L, Seow Y, Schapira AH et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011; 42:360–367. https://doi.org/10.1016/j.nbd.2011.01.029
Danzer KM, Kranich LR, Ruf WP et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener. 2012; 7:42. https://doi.org/10.1186/1750-1326-7-42
Straniero L, Rimoldi V, Samarani M et al. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep. 2017; 7:12702. https://doi.org/10.1038/s41598-017-12973-5